ARMP

Armata Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

4.910

-0.05(-1.008%)1D

Line

Candle

YTD

High

5.080

Open

5.080

VWAP

4.92

Vol

52.37K

Mkt Cap

177.89M

Low

4.700

Amount

257.85K

EV/EBITDA(TTM)

Total Shares

36.15M

285.72M

EV/OCF(TTM)

P/S(TTM)

25.87

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q1

1.47M

+19.03%

1.38M

-53.58%

1.38M

+42.86%

Estimates Revision

The market is revising No Change the revenue expectations for Armata Pharmaceuticals, Inc. (ARMP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 81.18%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+81.18%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast ARMP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARMP is 9.00 USD with a low forecast of 9.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 4.910

Low

9.00

Averages

9.00

High

9.00

Current: 4.910

Low

9.00

Averages

9.00

High

9.00

H.C. Wainwright

Buy

maintain

2025-10-22

Reason

H.C. Wainwright

Price Target

2025-10-22

maintain

Buy

Reason

H.C. Wainwright reiterates a Buy rating and $9 price target on Armata Pharmaceuticals after the company shared new data from the recently completed Phase 2a diSArm study in a late-breaking oral presentation at IDWeek 2025. These new in vitro data providing strong evidence for the efficacy of its core therapeutic strategy for AP-SA02, along with the broader dataset, support advancement into a pivotal Phase 3 trial set to begin in 2026, the analyst tells investors.

H.C. Wainwright

Buy

maintain

$7 -> $9

2025-05-19

Reason

H.C. Wainwright

Price Target

$7 -> $9

2025-05-19

maintain

Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-12-19

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-12-19

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-11-14

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-11-14

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Joseph Pantginis

Strong Buy

Reiterates

2024-11-12

Reason

HC Wainwright & Co.

Joseph Pantginis

Price Target

2024-11-12

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Armata Pharmaceuticals Inc (ARMP.A) is -3.36, compared to its 5-year average forward P/E of -2.95. For a more detailed relative valuation and DCF analysis to assess Armata Pharmaceuticals Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.95

Current PE

-3.36

Overvalued PE

-1.40

Undervalued PE

-4.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.04

Current EV/EBITDA

-8.94

Overvalued EV/EBITDA

-1.18

Undervalued EV/EBITDA

-4.90

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

30.78

Current PS

4.91

Overvalued PS

79.88

Undervalued PS

-18.32